EU CHMP recommends approval of Fiasp (rapid acting insulin aspart) for diabetes in adults- Novo Nordisk
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fiasp (rapid acting insulin aspart), from Novo Nordisk, for the treatment of diabetes in adults. The applicant for this medicinal product is Novo Nordisk A/S. Fiasp will be available as a solution for injection (100 units/ml).
The active substance of Fiasp is insulin aspart, a fast-acting insulin analogue which is absorbed more rapidly by the body and can therefore act faster than human insulin. The replacement insulin acts in the same way as naturally produced insulin; it works by facilitating uptake of glucose into skeletal muscle and fat tissue, and by inhibiting glucose output from the liver. The benefits with Fiasp are its ability to control blood glucose. The most common side effect is hypoglycemia.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma